Turoctocog alfa (NovoEight®)--from design to clinical proof of concept.

Turoctocog alfa (NovoEight®)--from design to clinical proof of concept.

Item
http://www.wikidata.org/entity/Q38209486
The pharmacokinetics of a B-domain truncated recombinant factor VIII, turoctocog alfa (NovoEight®), in patients with hemophilia A.Industrial production of clotting factors: Challenges of expression, and choice of host cells.Updates from guardian™: a comprehensive registration programme.Emerging drugs for the treatment of hemophilia A and B.2017 Clinical trials update: Innovations in hemophilia therapy.Molecular design and downstream processing of turoctocog alfa (NovoEight), a B-domain truncated factor VIII molecule.Interim results from a large multinational extension trial (guardian(™) 2) using turoctocog alfa for prophylaxis and treatment of bleeding in patients with severe haemophilia A.Pharmacokinetic-based prediction of real-life dosing of extended half-life clotting factor concentrates on hemophilia.
P2860

Turoctocog alfa (NovoEight®)--from design to clinical proof of concept.

Item
http://www.wikidata.org/entity/Q38209486
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Turoctocog alfa (NovoEight®)--from design to clinical proof of concept.
@en
type
label
Turoctocog alfa (NovoEight®)--from design to clinical proof of concept.
@en
prefLabel
Turoctocog alfa (NovoEight®)--from design to clinical proof of concept.
@en
P1433
P1476
P2093
P275
P2860
P304
P31
P356
P433
P478
P577
P5875
P698
P921
P932
P356
P1433
P1476
Turoctocog alfa (NovoEight®)--from design to clinical proof of concept.
@en
P2093
P275
P2860
P304
P31
P356
P433
P478
P577
P5875
P698
P921
P932